Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline
Home » Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline
Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline2021-11-112021-11-13http://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.pngRedPepper Mergershttp://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.png200px200px
VIEW ARTICLE If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.